U.S. Gastric Cancer Diagnostics Market Summary
The U.S. gastric cancer diagnostics market size was estimated at USD 489.09 million in 2024 and is projected to reach 897.20 million by 2033, and growing at a CAGR of 7.08% from 2025 to 2033. The U.S. gastric cancer diagnostics market is expanding due to advancements in diagnostic technologies, increasing awareness and patient education, and the expansion of healthcare infrastructure in emerging markets. According to the American Cancer Society (ACS) in 2024, gastric cancer accounted for 26,890 new cases and 10,880 deaths in the U.S. In addition, 30,300 new cases and 10,780 deaths are estimated in the U.S. for the year 2025.Technological innovations such as liquid biopsies, next-generation sequencing (NGS), and AI-based imaging are propelling the market growth. These tools enable early detection, improved staging, and better characterization of tumor biology, leading to more personalized and effective treatment plans. Advanced endoscopy techniques, like narrow-band imaging and confocal laser endomicroscopy, enhance diagnostic accuracy and patient outcomes. Integration of molecular diagnostics also allows for targeted therapies based on genetic profiles. As healthcare providers and researchers push for more precise, less invasive methods, technological progress boosts market demand, offering faster results, better sensitivity, and reduced patient discomfort compared to traditional methods.
Public awareness campaigns and educational initiatives led by governments, NGOs, and healthcare providers are further fueling market growth by improving recognition of gastric cancer symptoms and risk factors. One such example is Hope for Stomach Cancer, a national nonprofit organization that will play a key role at the May 2025 ASCO Annual Meeting, advancing early detection, treatment, and awareness of stomach and gastroesophageal cancers through advocacy, education, patient support, and national legislative partnerships. This increased awareness is prompting earlier medical consultations and higher participation in screening programs. Moreover, the rise in health literacy and access to online medical information empowers patients to seek timely diagnosis and appropriate care. As patients and caregivers become more proactive, the demand for accurate and accessible diagnostic services grows. This trend is vital in emerging economies, where awareness efforts are narrowing the gap in healthcare utilization and fueling market growth for diagnostic technologies.
The expansion of healthcare infrastructure associated with developing nations is one of the drivers in the U.S. gastric cancer diagnostics market through a different lens, namely, health equity and outreach. In the U.S., ongoing investments in healthcare infrastructure, especially in underserved and rural areas, are improving access to diagnostic services, including endoscopy and advanced imaging for gastric cancer. Federally funded programs and hospital network expansions aim to bridge disparities, enabling earlier detection and better outcomes in high-risk populations such as Asian American and Hispanic communities, where gastric cancer prevalence is comparatively higher. These efforts support market growth by increasing demand for diagnostic tools.
U.S. Gastric Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. gastric cancer diagnostics market report based on product, disease type, end use:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Reagents & Consumables
- Instruments
Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Adenocarcinoma
- Gastric lymphoma
- Others
End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Diagnostic imaging
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Gastric Cancer Diagnostics Market Variables, Trends & Scope
Chapter 4. U.S. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis
Chapter 6. U.S. Gastric Cancer Diagnostics Market: End use Estimates & Trend Analysis
Chapter 7. U.S. Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Illumina, Inc
- Guardant Health
- Natera, Inc
- Thermo Fisher Scientific
- QIAGEN
- Freenome Holdings Inc.
- Exact Sciences Corporation
- PathAI, Inc
- GE Healthcare
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 150 |
Published | June 2025 |
Forecast Period | 2024 - 2033 |
Estimated Market Value ( USD | $ 489.09 Million |
Forecasted Market Value ( USD | $ 897.2 Million |
Compound Annual Growth Rate | 7.0% |
Regions Covered | United States |
No. of Companies Mentioned | 9 |